These data highlight that the attenuation of the expression of BCL6 and pro-survival BCL2 members in addition to Myc expression contributes to the synergistic anti-cancer effects of combinations of AGN and Myc inhibitors, which may improve the outcomes of DLBCL treatment. Here, BCL6 is linked to diffuse large B-cell lymphoma.